Cipla recalls asthma drug in the US

The vials were manufactured by Cipla at its Pithampur manufacturing facility

Cipla has decided to recall 1,40,625 vials of Levalbuterol Inhalation Solution from the US market. The solution is used for relieving shortness of breath and coughing caused by asthma and chronic obstructive pulmonary disease.

The company is recalling the drug for failed impurities and degradation specifications, according to the information available on the USFDA website.

Reportedly, the vials were manufactured by Cipla at its Pithampur manufacturing facility, near Indore, for Princeton-based Dr Reddy's Laboratories.

The recall of the drugs has been initiated under Class-III which FDA defined as "a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences."